Prescribing information

 

In line with the National Homecare Medicines Committee (NHMC) Pharma-funded Homecare Services guidelines, Novartis has commissioned Pharmaxo and Healthcare at Home to provide homecare service to SPMS patients with active disease on MAYZENT.

Dispense and delivery

Homecare services will provide:

  • Flexible delivery to accommodate the needs of the patient and the clinical team
  • Options for home and alternative suitable delivery locations in the UK
  • Active prescription management if required by the clinical team
  • Proof of delivery to the agreed location
  • Visibility of service provider patient records, deliveries and statistics as required by the clinical team

Novartis welcomes the opportunity to support the implementation of MAYZENT homecare service in order to enhance the patient experience.

Please contact your Novartis patient access manager for further details.

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
SIP20-C001f May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]